Autophagic vacuolar myopathy
Rare genetic disorders causing progressive muscle weakness via autophagic buildup.
Autophagic vacuolar myopathy (AVM) is a group of rare genetic disorders characterized by common histological features on muscle biopsy, including vacuolar membranes with sarcolemmal characteristics and an excess of autophagic vacuoles. As of 2019, five types have been identified: Danon disease, X-linked myopathy with excessive autophagy (XMEA), infantile autophagic vacuolar myopathy, adult-onset autophagic vacuolar myopathy with multiorgan involvement, and sometimes a fifth type (e.g., associated with VMA21 mutations or others). These disorders are progressive, beginning with difficulty picking up small objects and advancing to trouble walking, with onset ranging from early childhood to late adulthood.
- types_identified
- 5 (as of 2019)
- mode_of_inheritance
- X-linked (Danon: dominant; XMEA: recessive)
- known_genes
- LAMP2 (Danon), VMA21 (XMEA)
- affected_population
- All ages, from early childhood to late adulthood
- key_symptom
- Progressive muscle weakness
Lore & Background
Autophagic vacuolar myopathy encompasses disorders caused by mutations in genes that slow the fusion between autophagic vacuoles and lysosomes, leading to accumulation of vacuoles and breakdown of muscle cells. Danon disease results from LAMP2 gene mutations, causing little to no LAMP-2 protein production, impairing transport into lysosomes. XMEA is linked to VMA21 gene mutations at Xq28. For infantile AVM and adult-onset AVM with multiorgan involvement, the specific genes remain unknown.
Reader's Guide
The significance of autophagic vacuolar myopathy lies in its representation of a class of genetic muscle disorders with shared pathological mechanisms—defective autophagy leading to muscle cell breakdown. Diagnosis is challenging due to overlapping symptoms with other neuromuscular diseases, requiring a combination of genetic testing, medical history review, physical exam, laboratory tests, and often muscle biopsy. Treatment currently relies on enzyme replacement therapy (ERT), which provides temporary relief, particularly for Pompe disease. Gene therapy is under active research as a potential future cure. The X-linked inheritance patterns of Danon disease and XMEA highlight important genetic counseling considerations: fathers cannot pass these traits to sons, and female carriers may show mild or no symptoms. The progressive nature of AVM, from fine motor difficulties to impaired walking, underscores the need for early detection and management.
Did You Know?
- Danon disease is caused by mutations in the LAMP2 gene, leading to little or no LAMP-2 protein production.
- XMEA is caused by mutations in the VMA21 gene and is inherited in an X-linked recessive pattern.
- Pompe disease is a separate lysosomal storage disorder caused by GAA deficiency, not classified among the five types of AVM.
- There is no approved enzyme replacement therapy for the AVM group; enzyme replacement therapy is used for Pompe disease, a distinct disorder.
More in Genetic diseases and disorders 1-24
Spotted an error? Know more?
This is a living reference — every entry is fact-audited, and reader corrections feed straight into our audit queue. Suggest an edit · See this site's audit record